Recombinant activated factor VII in clinical practice: a 2014 update

Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital hemophilia and inhibitors. Due to the initial success in this clinical setting, its use has been extended to other coagulopathies characterized by impaired thrombin generation, i....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and thrombolysis Jg. 39; H. 2; S. 235 - 240
Hauptverfasser: Franchini, Massimo, Crestani, Silvia, Frattini, Francesco, Sissa, Cinzia, Bonfanti, Carlo
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Boston Springer US 01.02.2015
Springer Nature B.V
Schlagworte:
Blood Coagulation - drug effects
Cardiology
Clinical Trials as Topic
Factor VII Deficiency - drug therapy
Factor VIIa - pharmacology
Hematology
Hemophilia A - drug therapy
Hemostatics - pharmacology
Humans
Medicine
Medicine & Public Health
Recombinant Proteins - pharmacology
Thrombasthenia - drug therapy
FVII deficiency
Recombinant activated FVII
rFVIIa
NovoSeven
Hemophilia
Acquired FVIII inhibitors
Glanzmann’s thrombasthenia
ISSN:0929-5305, 1573-742X, 1573-742X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital hemophilia and inhibitors. Due to the initial success in this clinical setting, its use has been extended to other coagulopathies characterized by impaired thrombin generation, i.e. acquired hemophilia, inherited factor VII deficiency and Glanzmann’s thrombasthenia, for which it is currently licensed. Extensive research in the last decade has increased our knowledge of the mechanisms utilized by rFVIIa to restore normal hemostasis. This paper reviews current understanding of the mechanisms of action of rFVIIa before summarizing the clinical experience, in terms of safety and efficacy, to date in its licensed indications.
Bibliographie:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0929-5305
1573-742X
1573-742X
DOI:10.1007/s11239-014-1114-1